))
CART therapy moving in a fast-paced market for advanced therapies after collaboration between Kite and Arcellx for multiple myeloma
Fetch error
Hmmm there seems to be a problem fetching this series right now.
Last successful fetch was on April 13, 2024 12:14 (
What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 362433361 series 3473072
Контент предоставлен seriously stem cells and Seriously stem cells. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией seriously stem cells and Seriously stem cells или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
In this episode, we're giving audiences an update on the latest news of stem cell technologies. The episode highlights the collaboration between a clinical-stage biotech company, Arcellx, and a biopharmaceutical giant, Kite, a Gilead company, on the CART therapy candidate targeting BCMA antigen on multiple myeloma (MM) known as CART-ddBCMA. The candidate is based on a proprietary platform technology D-Domain of Arcellx that aims to improve the efficiency and effective of CART target recognition. Here is more about the candidate in the episode based on the press conference news of Kite and Arcellx.
10 эпизодов
Поделиться
